Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 11, 1999, Pages 1221-1225

  Merkel, Carlo ^a   Sacerdoti, David ^b   Bolognesi, Massimo ^b   Buonamico, Paolo ^b   Sticca, Antonietta ^b   Amodio, Piero ^b   Angeli, Paolo ^b   Micotti, Lucia ^b   Gatta, Angelo ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b NONE

Author keywords

Beta blockers; Indocyanine green; Liver circulation; Liver function; Nitro derivatives; Portal hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INDOCYANINE GREEN; ISOSORBIDE MONONITRATE; NADOLOL; NITRATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATIC VEIN; HUMAN; LIVER BLOOD FLOW; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER CLEARANCE; LIVER FUNCTION; LIVER METABOLISM; LONG TERM CARE; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; VEIN CATHETERIZATION; VENOUS PRESSURE;

EID: 0032736491     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199911000-00006     Document Type: Article

References (24)

1. Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Torboli P, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996; 348:1677-1681.
2. Villanueva C, Balanzò J, Novella MT, Sorìano G, Sàìnz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334:1624-1629.
3. Tarver D, Walt RP, Dunk AA, Jenkons WJ, Sherlock S. Precipitation of hepatic encephalopathy by propranolol in cirrhosis. Br Med J 1983; 287:585.
4. van Buuen HR, Van der Velden PC, Koorevaar G, Silberbusch J. Propranolol increases arterial ammonia in liver cirrhosis. Lancet 1982; ii:951-952.
5. Merkel C, Sacerdoti D, Finucci GF, Zuin R, Bazzerla G, Bolognesi M, et al. Effect of nadolol on liver haemodynamics and function in patients with cirrhosis. Br J Clin Pharmacol 1986; 21:713-719.
6. Hayes PC, Critchon S, Shepherd AN, Bouchier IA. Propranolol in chronic liver disease: a controlled trial of its effect and safety over twelve months. Q J Med 1987; 65:823-834.
7. Merkel C, Gatta A, Sacerdoti D, Bolognesi M, Rondana M, Caregaro L, et al. Long-term effect of nadolol on quantitative liver function tests in patients with cirrhosis. Eur J Clin Pharmacol 1988; 34:501-504.
8. Durk AA, Moore J, Symon A, Dickie A, Sinclair TS, Mowat NA, et al. The effect of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 1988; 2:143-151.
9. Merkel C, Bolognesi M, Angeli P, Finucci GF, Amodio P, Bellon S, et al. Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis. Br J Clin Pharmacol 1990; 30:221 -227.
10. Garcia-Pagan JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991; 114:869-873.
11. Winkler K, Keiding S, Tygstrup N. Clearance as a quantitative measurement of liver function. In: The Liver: Quantitative Aspects of Structure and Function. Paumgartner P, Preisig R, (editors). Basol: Karger; 1973, pp. 144-155.
12. Bass L, Keiding S, Winkler K, Tygstrup N. Enzymatic elimination of substrates flowing through the intact liver. J Theor Bil 1976; 61:393-410.
13. Nielsen NC. Spectrophotometric determination of indocyanine green in plasma especially with a view to an improved correction for blank density. Scand J Clin Lab Invest 1963; 15:613-621.
14. Rowell LB. Measurement of hepatic splanchnic blood flow in man by dye dilution curves. In: Dye Curves: the Theory and Practice of Indicator Dilution. Bloomfield DA (editor). Baltimore: University Park Press; 1975. pp. 209-219.
15. Vorobioff J, Picabea E, Gamen G, Villavicencio R, Bordato J, Bessone F, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal hypertensive patients: long term hemodynamic and renal effects. Hepatology 1993; 18:477-484.
16. Morillas RM, Planas R, Cabré E, Galán A, Quer JC, Feu F, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology 1994; 20:1502-1508.
17. Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Hepatology 1997; 26:34-39.
18. Bosch J, Masti R, Kravetz D, Bruix J, Gaya J, Rigau J, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4:1200-1206.
19. Braillon A, Jiron MI, Valla D, Calés P, Lebrec D. Effect of propranolol on hepatic blood flow in patients with cirrhosis. Clin Pharmacol Ther 1985; 37:376-380.
20. Vinel JP, Caucanas JP, Calès P, Suduca JM, Voigt JJ, Pascal JP. Effect of propranolol on metabolic activity of the liver in patients with alcoholic cirrhosis. J Hepatol 1988; 7:186-192.
21. Keiding S. Hepatic clearance and liver blood flow. J Hepatol 1987; 4:393-398.
22. Bolognesi M, Secordoti D, Merkel C, Gatta A. Relationship between portal blood flow measured by image-directed Doppler ultrasonography and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis. J Clin Ultrasound 1995; 23:297-303.
23. Godellas CV, Fabri PJ, Knierim TH, Rosemurgy AS, Gower WR Jr. Hepatic function after porto-systemic shunt. J Surg Res 1992; 52:157-160.
24. Francois E, Garcia-Pagàn JC, Bru C, Feu F, Gilabert R, Escorsell A, et al. Efectos de la derivacion portosistemica intrahepatica sobre la hemodinamica esplancnica y sistemica en pacientes con hipertension portal. Gastroenterologia y Hepatelogia 1997; 20:1-4.